Genomic Biomarker Testing
Helomics offers a select group of clinically relevant protein expression and genetic mutation tests associated with drug response and disease prognosis. Only well-validated tests are included in our biomarker menu with citations of supporting literature provided in every test report. Physicians can select biomarkers for testing from carefully chosen panels of relevant tests, intuitively organized by cancer pathway and tumor type. Results for these tests are presented in a clear, easy to understand format, including summaries of the clinical relevance of each marker.
Helomics biomarker tests include the
most clinically relevant protein and molecular biomarkers which inform individual patient response and prognosis.
Biomarkers included in the Helomics portfolio are supported by current treatment guidelines, research, and insight from key opinion leaders.
​
Many physicians utilize biomarker test results to:
-
Choose between multiple, equivalent therapies for their patients
-
Make decisions on how aggressively to treat cancer
-
Suggest certain clinical trials for those patients that qualify
​
The tumor types most frequently tested through Helomics panel are gynecologic cancers, lung cancer, breast cancer, colon cancer, and pancreatic cancer, but the tests that comprise the Helomics Biomarker Panel can be performed on any solid tumor type.
Helomics Genomic Biomarker Panels
GYN
EGFR Pathway
-
KRAS (Mutation)
-
BRAF (Mutation)
-
PI3K (Mutation)
-
HER2
-
PTEN
DNA Repair
-
MMR Panel:
MLH1/MSH2/MSH6/
PMS2​
-
ERCC1
-
BRCA1
-
Topo2α
Angiogenesis
-
VEGF
-
CD31
-
PDGFRβ
Other
-
Ki-67
-
P53
LUNG
EGFR Pathway
-
EGFR (Mutation)
-
KRAS (Mutation)
-
BRAF (Mutation)
-
PI3K (Mutation)
-
PTEN
DNA Repair
-
ERCC1
-
TS
-
Topo2α
-
BRCA1
Angiogenesis
-
VEGF
-
CD31
-
PDGFRβ
Other
-
Ki-67
-
P53
-
ROS1 (FISH) (NSCLC Only)
COLON
EGFR Pathway
-
EGFR (Mutation)
-
KRAS (Mutation)
-
BRAF (Mutation)
-
PI3K (Mutation)
-
PTEN
DNA Repair
-
MMR Panel:
MLH1/MSH2/MSH6/
PMS2​
-
TS
Angiogenesis
-
VEGF
-
CD31
-
PDGFRβ
Other
-
Ki-67
-
P53
PANCREATIC
EGFR Pathway
-
EGFR (Mutation)
-
KRAS (Mutation)
DNA Repair
-
MMR Panel:
MLH1/MSH2/MSH6/
PMS2​
-
TS
-
Topo2α
Angiogenesis
-
VEGF
-
CD31
-
PDGFRβ
Other
-
Ki-67
-
P53
BREAST
EGFR Pathway
-
EGFR (Mutation)
-
PI3K (Mutation)
-
HER2
-
PTEN
DNA Repair
-
TS
-
Topo2α
-
BRCA1
Angiogenesis
-
VEGF
-
CD31
-
PDGFRβ
Other
-
Ki-67
-
P53
-
ER
-
PR
Utilizing Biomarker Results
Helomics biomarker results are presented in a clear, easy to understand format, including summaries of the clinical relevance of each test. Each patient report is generally delivered within 10-14 days of receiving the sample with all required paperwork, including signed test order form.
​
Hover or click in the gallery below to view pages from a sample report.
 BFx_Ovarian_Primary_Page_1 |  BFx_Ovarian_Primary_Page_2 |  BFx_Ovarian_Primary_Page_3 |
|---|---|---|
 BFx_Ovarian_Primary_Page_5 |  BFx_Ovarian_Primary_Page_6 |  BFx_Ovarian_Primary_Page_7 |
Useful, Easy to Read Information
Clinically Relevant: Only markers relevant to your patient's cancer type are included
Literature references provided, demonstrating link between marker and therapy
Well validated: All markers have strong clinical evidence supporting their use: many are included in guidelines
Results can be used in both the primary and recurrent settings